The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact
Current Oncology Reports · 14.05.2025 · 27 (6) · 774-787
DOI: 10.1007/s11912-025-01682-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Current Oncology Reports, online erschienen am 14.05.2025. Verfasst von Licheng Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Putuo district, Shanghai, 200065, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron Emission Tomography Computed Tomography, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE OF REVIEW: This review explores the clinical applications of PSMA-PET/CT in patients with intermediate to high-risk prostate cancer, focusing on its role in diagnostic reassessment, therapeutic redirection, and potential survival benefits. By evaluating its translational pathway, we aim to provide a structured analysis of its impact on patient management and treatment outcomes. RECENT FINDINGS: Prostate cancer remains a significant health challenge, and advancements in imaging techniques such as PSMA-PET/CT have shown promise in improving diagnostic accuracy and guiding treatment decisions. Emerging evidence highlights its superior sensitivity and specificity compared to conventional imaging, facilitating better staging, detection of metastases, and therapy selection. However, challenges persist in standardizing clinical applications, integrating findings into treatment guidelines, and addressing economic considerations. This review synthesizes the latest research findings and cost-effectiveness analyses to establish a comprehensive translational framework for PSMA-PET/CT in prostate cancer management. By consolidating diverse evidence, we aim to provide the medical community with clearer insights into its clinical utility, address ongoing controversies, and propose strategies to minimize treatment risks. The conclusions drawn from this study aspire to refine treatment protocols and enhance clinical outcomes for patients with this prevalent malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Putuo district, Shanghai, 200065, China.
- Department of Information Network Administration, Weifang People's Hospital, No.151 Guangwen Street, Weifang, Shandong, China.
- Department of Urology, Tongji Hospital, School of Medicine, Tongji University, 389 Xincun Road, Putuo district, Shanghai, 200065, China. wudenglong2009@tongji.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Wang, L., Wang, X., & Wu, D. (2025). The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact. Current Oncology Reports, 27(6), 774-787. https://doi.org/10.1007/s11912-025-01682-2
Vancouver
Wang L, Wang L, Wang X, Wu D. The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact. Current Oncology Reports. 2025;27(6):774-787. doi:10.1007/s11912-025-01682-2
BibTeX
@article{Wang2025,
author = {Wang, Licheng and Wang, Lizhun and Wang, Xin'an and Wu, Denglong},
title = {The Evolving Role of PSMA-PET/CT in Prostate Cancer Management: an Umbrella Review of Diagnostic Restaging, Therapeutic Redirection, and Survival Impact},
journal = {Current Oncology Reports},
year = {2025},
volume = {27},
number = {6},
pages = {774--787},
doi = {10.1007/s11912-025-01682-2}
}
EUVIMED